公开(公告)号：US20210179703A1

公开(公告)日：2021-06-17

申请号：US17164384

申请日：2021-02-01

申请人： Janssen Biotech, Inc.

发明人： Dennis Fitzgerald ,  Jay Siegel ,  Newman Yeilding

IPC分类号： C07K16/24 ,  A61K9/00 ,  G01N33/00 ,  A61P17/06 ,  A61K31/519 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

摘要： A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US11208474B2

公开(公告)日：2021-12-28

申请号：US15813767

申请日：2017-11-15

申请人： Janssen Biotech, Inc.

发明人： Dennis Fitzgerald ,  Newman Yeilding ,  Jay Siegel

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K9/00 ,  G01N33/00 ,  A61P17/06 ,  A61K31/519 ,  A61K45/06 ,  C07K16/28 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

摘要： A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US11197913B2

公开(公告)日：2021-12-14

申请号：US16993556

申请日：2020-08-14

申请人： Janssen Biotech, Inc.

发明人： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K38/20 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

摘要： A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US10765724B2

公开(公告)日：2020-09-08

申请号：US15471790

申请日：2017-03-28

申请人： Janssen Biotech, Inc.

发明人： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC分类号： A61K38/20 ,  A61K39/395 ,  C07K16/24 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

摘要： A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US20180036379A1

公开(公告)日：2018-02-08

申请号：US15471790

申请日：2017-03-28

申请人： Janssen Biotech, Inc.

发明人： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC分类号： A61K38/20 ,  C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A01K67/027 ,  C07K14/54

摘要： A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.